BioSpace News Archive

AbbVie (NYSE: ABBV), today announced extended long-term data from the Phase 3 RESONATE-2 study (PCYC-1115/1116) evaluating single-agent IMBRUVICA (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4, 2021

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it will present new data on its latest scientific innovations in cfDNA testing at the American Transplant Congress’ (ATC) 2021 Virtual Connect, taking place June 4-9, 2021.

Ichnos Sciences Inc., a global biotechnology company developing innovative biologics in oncology and autoimmune diseases, today presented preclinical data that support the potential of ISB 1342, a first-in-class bispecific T-cell engager targeting CD38 expressed on the surface of multiple myeloma (MM) cells.

Catalent, Inc., the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, announced that John Chiminski, Chair and Chief Executive Officer, will virtually present at the Biopharma CEO Investor Forum at 9:45 a.m. ET on June 8, 2021.

Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Amgen to be a specialty pharmacy partner for LUMAKRAS™.

Magenta Therapeutics, a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, announced additional positive results from a Phase 2 clinical trial of MGTA-145 and plerixafor in patients with multiple myeloma at the American Society of Clinical Oncology Annual Meeting, being held virtually June 4-8, 2021.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study evaluating Trodelvy® (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC)

Exelixis, Inc. (NASDAQ: EXEL) today announced promising phase 2 results for CABOMETYX® (cabozantinib) in combination with Bristol Myers Squibb’s OPDIVO® (nivolumab) in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC) from an investigator-sponsored trial.

Today CreakyJoints®, the digital, international patient community for people with all forms of arthritis and part of the Global Healthy Living Foundation, is presenting data from two posters that show people living with autoimmune forms of arthritis appreciate the effect of their medication and express satisfaction with disease control.